Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study
Netakimab is a humanized anti-interleukin-17А monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis. Herein, we report the accumulated efficacy data and safety findings of 54-week netakimab treatment during the PATERA study.The ai...
| প্রধান লেখক: | , , , , , , , , , |
|---|---|
| বিন্যাস: | প্রবন্ধ |
| ভাষা: | Russian |
| প্রকাশিত: |
IMA PRESS LLC
2021-03-01
|
| মালা: | Научно-практическая ревматология |
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://rsp.mediar-press.net/rsp/article/view/2989 |